Alan J. Koletsky

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 262 citations · Full text

Phase II Trial of Weekly Vinorelbine and Trastuzumab as First-Line Therapy in Patients with HER2+ Metastatic Breast Cancer

Mohammad Jahanzeb, Joanne Mortimer, Furhan Yunus et al. · The Oncologist · 2002 · 144 citations · Full text

Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer.

Jeffrey Crawford, Mark Allen O’Rourke, Joan H. Schiller et al. · Journal of Clinical Oncology · 1996 · 124 citations

Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer

Bruce Montgomery, Mario A. Eisenberger, Matthew B. Rettig et al. · Clinical Cancer Research · 2015 · 79 citations

Second neoplasms in patients with Hodgkin's disease following combined modality therapy--the Yale experience.

Alan J. Koletsky, Joseph R. Bertino, Leonard R. Farber et al. · Journal of Clinical Oncology · 1986 · 55 citations

Hematological Malignancy, Lymphoid Neoplasia, Actuarial Survival +15